Leukocyte Counts, Myeloperoxidase, and Pregnancy-Associated Plasma Protein A as Biomarkers for Cardiovascular Disease: Towards a Multi-BiomarkerApproach
Corresponding Author
M. B. I. Lobbes
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorM. E. Kooi
Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorE. Lutgens
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorA. W. Ruiters
Department of Cardiology, Orbis Medical Center, P.O. Box 5500, 6130 MB Sittard, The Netherlands
Search for more papers by this authorV. Lima Passos
Department of Methodology and Statistics, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorS. H. J. G. Braat
Department of Cardiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorM. Rousch
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorH. Ten Cate
Department of Internal Medicine, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorJ. M. A. van Engelshoven
Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorM. J. A. P. Daemen
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorS. Heeneman
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorCorresponding Author
M. B. I. Lobbes
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorM. E. Kooi
Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorE. Lutgens
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorA. W. Ruiters
Department of Cardiology, Orbis Medical Center, P.O. Box 5500, 6130 MB Sittard, The Netherlands
Search for more papers by this authorV. Lima Passos
Department of Methodology and Statistics, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorS. H. J. G. Braat
Department of Cardiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorM. Rousch
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorH. Ten Cate
Department of Internal Medicine, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorJ. M. A. van Engelshoven
Department of Radiology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands maastrichtuniversity.nl
Search for more papers by this authorM. J. A. P. Daemen
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorS. Heeneman
Department of Pathology, Cardiovascular Research Institute Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands carim.unimaas.nl
Search for more papers by this authorAbstract
We evaluated leukocyte counts and levels of CRP, fibrinogen, MPO, and PAPP-A in patients with stable and unstable angina pectoris, acute myocardial infarction, and healthy controls. All biomarkers were analyzed again after 6 months. Leukocyte counts and concentrations of fibrinogen, CRP, MPO, and PAPP-A were significantly increased in patients with acute myocardial infarction. Leukocyte counts and concentrations of MPO were significantly increased in patients with unstable angina pectoris compared with controls. After 6 months, leukocyte counts and MPO concentrations were still increased in patients with acute myocardial infarction when compared to controls. Discriminant analysis showed that leukocyte counts, MPO, and PAPP-A concentrations classified study group designation for acute coronary events correctly in 83% of the cases. In conclusion, combined assessment of leukocyte counts, MPO, and PAPP-A was able to correctly classify acute coronary events, suggesting that this could be a promising panel for a multibiomarker approach to assess cardiovascular risk.
References
- 1 Hansson G. K., Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease, The New England Journal of Medicine. (2005) 352, no. 16, 1685–1695, https://doi.org/10.1056/NEJMra043430, 2-s2.0-17644412023.
- 2 Lusis A. J., [email protected], Atherosclerosis, Nature. (2000) 407, no. 6801, 233–241, 2-s2.0-0033962963, https://doi.org/10.1038/35025203.
- 3 Weber C., Zernecke A., and Libby P., The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models, Nature Reviews Immunology. (2008) 8, no. 10, 802–815, https://doi.org/10.1038/nri2415, 2-s2.0-52949118482.
- 4 Koenig W. and Khuseyinova N., Biomarkers of atherosclerotic plaque instability and rupture, Arteriosclerosis, Thrombosis, and Vascular Biology. (2007) 27, no. 1, 15–26, https://doi.org/10.1161/01.ATV.0000251503.35795.4f, 2-s2.0-33847612773.
- 5 Ridker P. M., High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease, Circulation. (2001) 103, no. 13, 1813–1818, 2-s2.0-0035799331.
- 6 Danesh J., [email protected], Lewington S., Thompson S. G. et al., Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis, Journal of the American Medical Association. (2005) 294, no. 14, 1799–1809, 2-s2.0-0037322022, https://doi.org/10.1001/jama.294.14.1799.
- 7 Danesh J., Collins R., Appleby P., and Peto R., Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies, Journal of the American Medical Association. (1998) 279, no. 18, 1477–1482, https://doi.org/10.1001/jama.279.18.1477, 2-s2.0-0032513756.
- 8 Yarnell J. W. G., Patterson C. C., Sweetnam P. M., and Lowe G. D. O., Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies, European Heart Journal. (2004) 25, no. 12, 1049–1056, https://doi.org/10.1016/j.ehj.2004.04.011, 2-s2.0-3042747900.
- 9 Danesh J., Wheeler J. G., Hirschfield G. M. et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, The New England Journal of Medicine. (2004) 350, no. 14, 1387–1397, https://doi.org/10.1056/NEJMoa032804, 2-s2.0-1842587885.
- 10 Smith G. D., Harbord R., Milton J., Ebrahim S., and Sterne J. A. C., Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies, Arteriosclerosis, Thrombosis, and Vascular Biology. (2005) 25, no. 10, 2228–2233, https://doi.org/10.1161/01.ATV.0000183937.65887.9c, 2-s2.0-26244442855.
- 11 Baldus S., Heeschen C., Meinertz T. et al., Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes, Circulation. (2003) 108, no. 12, 1440–1445, https://doi.org/10.1161/01.CIR.0000090690.67322.51, 2-s2.0-0141727730.
- 12 Iversen K. K., [email protected], Teisner A. S., Teisner B. et al., Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction, American Journal of Cardiology. (2008) 101, no. 10, 1389–1394, 2-s2.0-34547772153, https://doi.org/10.1016/j.amjcard.2008.01.015.
- 13 Consuegra-Sanchez L., Fredericks S., and Kaski J. C., Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk, Atherosclerosis. (2009) 203, no. 2, 346–352, https://doi.org/10.1016/j.atherosclerosis.2008.07.042, 2-s2.0-62649135518.
- 14 Teruel J. L., Sabater J., Galeano C. et al., The Cockcroft-Gault equation is better than MDRD equation to estimate the glomerular filtration rate in patients with advanced chronic renal failure, Nefrologia. (2007) 27, no. 3, 313–319, 2-s2.0-34848830883.
- 15 Haim M., Boyko V., Goldbourt U., Battler A., and Behar S., Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study, Archives of Internal Medicine. (2004) 164, no. 4, 433–439, https://doi.org/10.1001/archinte.164.4.433, 2-s2.0-1242275178.
- 16 Barron H. V., Harr S. D., Radford M. J., Wang Y., and Krumholz H. M., The association between white blood cell count and acute myocardial infarction mortality in patients ≥65 years of age: findings from the cooperative cardiovascular project, Journal of the American College of Cardiology. (2001) 38, no. 6, 1654–1661, https://doi.org/10.1016/S0735-1097(01)01613-8, 2-s2.0-0035890034.
- 17 Bayes-Genis A., Conover C. A., Overgaard M. T. et al., Pregnancy-associated plasma protein A as a marker of acute coronary syndromes, The New England Journal of Medicine. (2001) 345, no. 14, 1022–1029, https://doi.org/10.1056/NEJMoa003147, 2-s2.0-0035807592.
- 18 Schindhelm R. K., Van der Zwan L. P., Teerlink T., and Scheffer P. G., Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?, Clinical Chemistry. (2009) 55, no. 8, 1462–1470, https://doi.org/10.1373/clinchem.2009.126029, 2-s2.0-68149168582.
- 19 Zhang R., Brennan M.-L., Fu X. et al., Association between myeloperoxidase levels and risk of coronary artery disease, Journal of the American Medical Association. (2001) 286, no. 17, 2136–2142, 2-s2.0-0035824162.
- 20 Brennan M.-L., Penn M. S., Van Lente F. et al., Prognostic value of myeloperoxidase in patients with chest pain, The New England Journal of Medicine. (2003) 349, no. 17, 1595–1604, https://doi.org/10.1056/NEJMoa035003, 2-s2.0-0142089171.
- 21 Morrow D. A., Sabatine M. S., Brennan M.-L. et al., Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18, European Heart Journal. (2008) 29, no. 9, 1096–1102, https://doi.org/10.1093/eurheartj/ehn071, 2-s2.0-45349099743.
- 22 Wong N. D., Gransar H., Narula J. et al., Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events, JACC: Cardiovascular Imaging. (2009) 2, no. 9, 1093–1099, https://doi.org/10.1016/j.jcmg.2009.05.012, 2-s2.0-70249144887.
- 23 Mocatta T. J., Pilbrow A. P., Cameron V. A. et al., Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction, Journal of the American College of Cardiology. (2007) 49, no. 20, 1993–2000, https://doi.org/10.1016/j.jacc.2007.02.040, 2-s2.0-34248374428.
- 24 Cavusoglu E., Ruwende C., Eng C. et al., Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome, American Journal of Cardiology. (2007) 99, no. 10, 1364–1368, https://doi.org/10.1016/j.amjcard.2006.12.060, 2-s2.0-34247624608.
- 25 Ruef J., März W., and Winkelmann B. R., Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study), Scandinavian Cardiovascular Journal. (2006) 40, no. 5, 274–279, https://doi.org/10.1080/14017430600925300, 2-s2.0-33749419349.
- 26 Lund J., Qin Q.-P., Ilva T. et al., Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation, Circulation. (2003) 108, no. 16, 1924–1926, https://doi.org/10.1161/01.CIR.0000096054.18485.07, 2-s2.0-0142023865.
- 27 Heeschen C., Dimmeler S., Hamm C. W., Fichtlscherer S., Simoons M. L., and Zeiher A. M., Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis, Journal of the American College of Cardiology. (2005) 45, no. 2, 229–237, https://doi.org/10.1016/j.jacc.2004.09.060, 2-s2.0-11844274732.
- 28 Consuegra-Sanchez L., Petrovic I., Cosin-Sales J., Holt D. W., Christiansen M., and Kaski J. C., [email protected], Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris, Clinica Chimica Acta. (2008) 391, no. 1-2, 18–23, 2-s2.0-33748334352, https://doi.org/10.1016/j.cca.2008.01.012.
- 29 Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M., Ferrer J., and Vargas M., Circulating pregnancy-associated plasma protein a is not an early marker of acute myocardial infarction, Clinical Biochemistry. (2005) 38, no. 2, 180–182, https://doi.org/10.1016/j.clinbiochem.2004.10.015, 2-s2.0-11844305012.
- 30 Wittfooth S., Qin Q.-P., Lund J. et al., Immunofluorometric point-of-care assays for the detection of acute coronary syndrome-related noncomplexed pregnancy-associated plasma protein A, Clinical Chemistry. (2006) 52, no. 9, 1794–1801, https://doi.org/10.1373/clinchem.2006.070607, 2-s2.0-33748334352.
- 31 Qin Q.-P., Wittfooth S., and Pettersson K., Measurement and clinical significance of circulating PAPP-A in ACS patients, Clinica Chimica Acta. (2007) 380, no. 1-2, 59–67, https://doi.org/10.1016/j.cca.2007.02.036, 2-s2.0-33947657288.
- 32 Wang T. J., [email protected], Gona P., Larson M. G. et al., Multiple biomarkers for the prediction of first major cardiovascular events and death, New England Journal of Medicine. (2006) 355, no. 25, 2631–2639, 2-s2.0-0142053961, https://doi.org/10.1056/NEJMoa055373.
- 33 Varo N., De Lemos J. A., Libby P. et al., Soluble CD40L: risk prediction after acute coronary syndromes, Circulation. (2003) 108, no. 9, 1049–1052, https://doi.org/10.1161/01.CIR.0000088521.04017.13, 2-s2.0-0041315652.
- 34 Ardigo D., Assimes T. L., Fortmann S. P. et al., Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease, Physiological Genomics. (2007) 31, no. 3, 402–409, 2-s2.0-33748479022, https://doi.org/10.1152/physiolgenomics.00104.2007.
